The Manufacturers Life Insurance Company Makes New $115.35 Million Investment in Boston Scientific Corporation $BSX

The Manufacturers Life Insurance Company acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 2,702,583 shares of the medical equipment provider’s stock, valued at approximately $115,346,000.

Other institutional investors also recently modified their holdings of the company. Sone Capital Management LLC bought a new position in shares of Boston Scientific in the second quarter valued at approximately $1,016,000. L2 Asset Management LLC acquired a new stake in Boston Scientific during the 2nd quarter valued at $362,000. Vega Investment Solutions bought a new position in Boston Scientific in the 2nd quarter valued at $477,000. Cetera Trust Company N.A acquired a new position in Boston Scientific in the second quarter worth $32,000. Finally, Aberdeen Wealth Management LLC acquired a new position in Boston Scientific in the second quarter worth $329,000. Institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of research reports. UBS Group lowered their target price on Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. TD Cowen reiterated a “buy” rating and set a $56.00 price target on shares of Boston Scientific in a research report on Tuesday. Raymond James Financial reissued an “outperform” rating and set a $57.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. Wolfe Research cut shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $60.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Trading Up 1.7%

Shares of BSX opened at $49.86 on Wednesday. The stock’s fifty day simple moving average is $46.44 and its 200-day simple moving average is $57.14. The firm has a market capitalization of $72.26 billion, a PE ratio of 20.19, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company’s revenue was up 7.5% on a year-over-year basis. During the same period last year, the company earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its board has approved a share repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.

Insider Activity

In other Boston Scientific news, Director Edward J. Ludwig purchased 5,000 shares of the stock in a transaction dated Friday, July 31st. The stock was bought at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Michael F. Mahoney purchased 186,240 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have acquired 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.